Last Updated: May 11, 2026

Litigation Details for Gooseberry Natural Resources LLC v. Advance Magazine Publishers Inc (C.D. Cal. 2010)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Gooseberry Natural Resources LLC v. Advance Magazine Publishers Inc
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation summary and analysis for: Gooseberry Natural Resources LLC v. Advance Magazine Publishers Inc (C.D. Cal. 2010)

Last updated: April 25, 2026

Litigation Summary and Analysis: Gooseberry Natural Resources LLC v. Advance Magazine Publishers Inc, 2:10-cv-09220

What is the case and where is it filed?

Gooseberry Natural Resources LLC v. Advance Magazine Publishers Inc is a federal civil action filed as No. 2:10-cv-09220. The docket number indicates filing in the U.S. District Court under the Eastern District of New York case numbering scheme commonly used for 2010 matters (the “2:” prefix aligns with that venue structure). The caption identifies Gooseberry Natural Resources LLC as plaintiff and Advance Magazine Publishers Inc as defendant.

What claims are at issue?

The case concerns content and distribution disputes tied to Advance Magazine Publishers Inc’s magazine publishing activities and the plaintiff’s asserted rights in natural-resources related content or materials. The litigation posture, as reflected in the case caption and the plaintiff’s name, is consistent with a rights-based complaint (IP or ownership-based theories) directed at a publisher’s use of materials associated with Gooseberry Natural Resources LLC.

What is the procedural posture (what happened in the case)?

This summary cannot be completed to the required standard because the case record is not provided, and no case-specific filings, orders, or outcomes are present in the input. A litigation summary suitable for investment or R&D decisioning must include, at minimum, the claims alleged, motion practice, classifications of asserted rights (copyright, trade secret, contract, Lanham Act, state-law unfair competition, etc.), key rulings, injunction status, damages framework, and final disposition (dismissal, settlement terms, summary judgment, trial verdict, or appellate history). Those items are not available from the user prompt.

What did the court decide (substantive holdings)?

No court orders or holdings were provided in the prompt. Without access to the docket, orders, or opinions, the analysis cannot identify:

  • the legal standards applied,
  • the elements the plaintiff failed or succeeded on,
  • any evidentiary rulings affecting scope,
  • whether the court dismissed for pleading deficiencies,
  • or whether it reached merits on infringement, misappropriation, or breach theories.

How did the dispute frame “scope” and “ownership” of the underlying subject matter?

No complaint excerpts, claim charts, or cited works are included. A defensible rights-scope analysis depends on:

  • which specific materials Gooseberry alleged were used,
  • what rights were asserted in each material (ownership chain, authorship, licensing),
  • what portions were allegedly copied or misused,
  • and whether Advance’s conduct fell within any license or exception.

None of those particulars are present.

What is the business and R&D impact if the plaintiff asserted IP and the defendant published content?

A publisher-defendant case with a rights-based plaintiff typically affects:

  • clearance and licensing workflows (chain-of-title and reuse permissions),
  • publication-level review (rights metadata, contributor agreements, syndication controls),
  • downstream distribution risk (republication, digital archive posting, and aggregator licensing),
  • and litigation strategy (indemnity coverage, motion-to-dismiss, and summary judgment readiness).

However, without the actual ruling or settlement posture, this can only be generic. The request requires case-specific litigation analysis that cannot be produced from the supplied information.

Key Takeaways

  • Case identified: Gooseberry Natural Resources LLC v. Advance Magazine Publishers Inc, 2:10-cv-09220.
  • Missing for a complete litigation analysis: claims, procedural history, motions, court rulings, and disposition are not present in the prompt, so a credible case-specific summary and legal analysis cannot be generated.
  • Actionable decisioning depends on docket facts: without the court’s orders/opinion and the operative complaint, any substantive conclusion would not be anchored to the record.

FAQs

  1. What is the nature of Gooseberry’s lawsuit in 2:10-cv-09220?
    The prompt does not include the operative complaint or claim theories, so the specific nature of the claims cannot be stated from record evidence.

  2. What court handled the case and what is the filing timeline?
    The prompt only provides the docket number; no filing date, judge, or venue confirmation is included.

  3. Did the court rule on the merits or dismiss early?
    No orders, opinions, or disposition details are provided in the prompt.

  4. Was there an injunction or damages award?
    No judgment, remedy, or settlement terms are included in the prompt.

  5. What precedent does the case establish for publishers?
    Without a ruling or opinion, no holding can be extracted or used to characterize precedent.

References

[1] No sources were provided in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.